503A vs 503B Compounding: What Clinics Need to Know
Understanding the regulatory difference between 503A compounding pharmacies and 503B outsourcing facilities is essential for any clinic sourcing compounded preparations. This guide explains both pathways and what documentation to require.
Written by Benn Bluestein-Veyra, M.Sc. Organic Chemistry Founder, ExaVeyra Sciences
What Is Pharmaceutical Compounding?
Pharmaceutical compounding is the process of creating a customized medication for a specific patient or clinical need combining, mixing, or altering ingredients to meet requirements that commercially available, FDA-approved drugs cannot address. Compounding has been practiced by pharmacists for centuries and remains a critical tool in modern clinical medicine.
Compounding is the pathway for prescription preparations in strengths or dosage forms that are not commercially available. The Drug Quality and Security Act (DQSA) of 2013 formalized two distinct regulatory frameworks for compounding, Section 503A and Section 503B, each governing a different type of compounding operation with different compliance requirements.
Understanding which framework governs your supplier, and what documentation obligations flow from each, is essential for any clinic building a compliant regenerative medicine practice.
A compounded preparation can change the dose, change the dosage form, such as a cream in place of a tablet, or leave out an ingredient a patient cannot tolerate. The 503A and 503B sections match the level of oversight to the scale and risk profile of that work.
503A Compounding Pharmacies
Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. A 503A pharmacy prepares compounded medications for individual patients based on valid prescriptions from licensed practitioners. The patient-prescription relationship is central to 503A each compounded preparation must be tied to a specific patient's documented medical need.
503A pharmacies operate primarily under state pharmacy board oversight, though they must comply with applicable federal law including using bulk drug substances that meet a USP or NF monograph, are components of an approved drug, or appear on FDA's 503A bulks list. They follow USP standards most importantly USP 797 for sterile compounding, USP 795 for non-sterile compounding, and USP 800 for hazardous drug handling. They are not required to register with the FDA and are generally inspected by state pharmacy boards rather than federal inspectors.
For clinics, the key practical constraint of 503A is that you cannot maintain clinic inventory of 503A compounded products without patient-specific prescriptions. Each order must correspond to an identified patient with a valid prescription. Interstate distribution is generally limited, though specific exemptions apply.
The FDA holds authority over a 503A pharmacy in certain circumstances, for example when a compounded drug crosses state lines. Licensure and day-to-day inspection remain a state board matter, which gives 503A its own oversight structure.
503A Key Facts
- Patient-specific prescription required for each preparation
- State pharmacy board oversight (not FDA registration)
- USP 795 / 797 / 800 compliance standards
- Interstate dispensing requires a non-resident pharmacy license in the destination state
- Cannot supply bulk office-use inventory without prescriptions
- Best for: customized patient-specific formulations
503B Outsourcing Facilities
Section 503B created a new category of compounding entity the outsourcing facility that voluntarily registers with the FDA and operates under Current Good Manufacturing Practice (cGMP) standards comparable to those applied to commercial pharmaceutical manufacturers. This registration enables 503B facilities to produce compounded medications in large batches without individual patient prescriptions and to ship across state lines.
A 503B outsourcing facility may supply compounded drugs to a clinic as office stock, without a prescription for each patient, within the limits section 503B sets. Biological products licensed under section 351 of the Public Health Service Act fall outside both compounding pathways, so neither a 503A pharmacy nor a 503B facility compounds them.
503B facilities are subject to regular FDA inspections, must comply with 21 CFR Parts 210 and 211 (cGMP regulations), and must submit adverse event reports. Their FDA registration status is publicly searchable, and their inspection records are available through FDA's database. A clinic weighing either pathway can check a facility's registration and inspection history the same way.
503B Key Facts
- No individual patient prescription required for clinic supply
- FDA registration required voluntary but enables bulk production
- cGMP manufacturing standards (21 CFR 210/211)
- Regular FDA inspections
- Interstate shipping permitted nationwide
- Can supply clinic inventory for office use
- Best for: high-volume clinic sourcing and inventory
503B Oversight Brings Pharmaceutical-Grade Release Testing to Larger Batches
The Drug Quality and Security Act of 2013 created 503B as a middle tier between pharmacy compounding and full pharmaceutical manufacturing. In exchange for broader distribution, an outsourcing facility accepts direct FDA authority and cGMP standards.
In practice, cGMP means FDA inspections, validated sterile processes and dedicated cleanroom environments. It also means environmental monitoring programs and lot-specific release testing for potency, sterility and endotoxins.
A 2025 analysis in Missouri Medicine, written by a quality assurance director at a 503B facility, credits these controls with reducing the risk of contamination and subpotent formulations. For a clinic, the same list works as a checklist when reviewing any compounder's quality file.
503A vs 503B Side-by-Side Comparison
Key regulatory differences at a glance.
| Attribute | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Regulatory Oversight | State pharmacy board | FDA (federal) |
| Prescription Required | Yes, patient-specific | No, office stock permitted |
| Batch Size | Small patient-specific | Large bulk manufacturing |
| Manufacturing Standard | USP 795 / 797 / 800 | cGMP (21 CFR Parts 210/211) |
| FDA Registration | Not required | Required voluntary registration |
| Interstate Shipping | Generally limited | Permitted nationwide |
| FDA Inspections | State board inspections | Regular FDA inspections |
| Clinic Inventory | Generally not permitted | Permitted for office use |
| Best For | Patient-specific formulations | Clinic stock, high-volume use |
| Distribution to Hospitals | Patient-specific dispensing only | Permitted |
| Sterility Testing | Varies by state | Required for each lot |
Shortage Status Opens and Closes Each Compounding Window
Federal shortage listings decide when a pharmacy may compound a copy of an approved drug. The sequence below shows how one window opens and closes while the patient-specific pathway stays in place.
2013
The Drug Quality and Security Act creates the 503B outsourcing facility category beside traditional 503A compounding.
Shortage listed
While the FDA lists an approved drug in shortage, both 503A pharmacies and 503B facilities may compound copies of it.
Shortage resolved
Once the FDA removes the drug from the list, the shortage-based authorization ends and compounding of copies winds down.
Wind-down
The FDA sets a separate deadline for each pathway, and the 503A deadline has fallen before the 503B deadline.
Afterward
The patient-specific 503A pathway remains open for unmet clinical needs documented on an individual prescription.
For the dated shortage timeline and the safety data behind it, read GLP-1 and Compounded Peptides After the 2026 503A Shakeup.
What Documentation to Require from Your Supplier
Whether sourcing from a 503A or 503B facility, your clinic should always require the following documentation before placing orders. This protects your practice, your patients, and your compliance standing.
503B Required Documents
- FDA registration number (verify at fda.gov)
- cGMP compliance documentation
- Certificate of Analysis (COA) per lot
- Lot number and expiration date
- Sterility test results
- Potency and purity test results
503A Required Documents
- State pharmacy license (active, current state)
- USP 797 compliance documentation
- Certificate of Analysis (COA)
- Lot number and expiration date
- Valid prescription documentation process
- Beyond-use dating (BUD) data
Five Questions Confirm Any Compounder's Pathway and Quality
These questions turn the 503A and 503B distinction into a sourcing conversation. Each answer can be checked against a public record or a lot document.
- 01
Is this a 503A pharmacy or a 503B outsourcing facility?
The answer sets the regulatory framework and the level of oversight.
- 02
Can you provide a Certificate of Analysis for this lot?
A lot COA confirms batch-specific potency, sterility and endotoxin results.
- 03
What is the source and form of the active pharmaceutical ingredient?
Form matters, since the salt and base forms of one molecule have different properties.
- 04
When was the facility last inspected, and by whom?
A state board inspects a 503A pharmacy, and the FDA inspects a 503B facility. Inspection records can be requested.
- 05
Does the facility appear on the FDA's registered outsourcing facility list?
For a 503B facility, the FDA publishes that list on fda.gov, and the check takes about a minute.
How ExaVeyra Sciences Sources Compounded Preparations
ExaVeyra Sciences works only with a 503A pharmacy licensed by its state Board of Pharmacy, which compounds against a valid prescription for an individual patient. ExaVeyra does not work with a 503B outsourcing facility and does not supply compounded preparations as office stock. The pharmacy is vetted for licensure, manufacturing documentation, and COA quality before any preparation enters our catalog.
Our sourcing process is reviewed by our founder an M.Sc. organic chemist with a background in analytical chemistry and nucleotide process chemistry. We evaluate not just whether a supplier has a COA, but whether the analytical methodology behind that COA is sound HPLC purity data, mass spectrometric identity confirmation, endotoxin testing, and stability data are all part of our evaluation framework.
For wholesale partners, we provide lot numbers and COA documentation for exosome formulations, and our 503A pharmacy partner documents each compounded preparation it dispenses.
503A & 503B FAQ
- What is the main difference between 503A and 503B compounding?
- 503A pharmacies prepare patient-specific compounded medications based on individual prescriptions under state pharmacy board oversight. 503B outsourcing facilities manufacture medications in bulk under FDA cGMP standards, can ship interstate without individual prescriptions, and supply clinics with office-use products. The key practical difference: 503B products do not require a patient-specific prescription and can be held as clinic inventory.
- Can a clinic order compounded peptides without a patient prescription?
- Through a 503B outsourcing facility, yes: 503B products can be supplied to clinics for office use without individual patient prescriptions. Through a 503A pharmacy, a patient-specific prescription is required. Many clinics use 503B sourcing for office-use inventory and 503A for patient-specific compounded formulations.
- What is a 503B outsourcing facility?
- A 503B outsourcing facility is an FDA-registered manufacturer that voluntarily registers with the FDA and produces compounded medications in bulk under Current Good Manufacturing Practice (cGMP) standards. They undergo FDA inspections, can produce medications without individual prescriptions, and may ship across state lines. They are subject to stricter oversight than 503A pharmacies.
- What is a 503A compounding pharmacy?
- A 503A pharmacy prepares compounded medications for individual patients based on valid prescriptions from licensed practitioners. They operate under state pharmacy board oversight and follow USP standards (USP 795, 797, 800). They cannot produce large batches for distribution without prescriptions and are generally limited to intrastate distribution.
- Who inspects a 503A pharmacy, and who inspects a 503B facility?
- A state board of pharmacy licenses and inspects a 503A pharmacy, and the FDA holds authority in certain circumstances, such as interstate shipment. The FDA inspects a 503B outsourcing facility against cGMP, including validated sterile processes, environmental monitoring and lot-specific release testing.
- What documentation should I require from a 503A/503B supplier?
- For 503B products: FDA registration number, cGMP compliance documentation, certificates of analysis (COA) for each lot, lot numbers, expiration dates, and sterility test results. For 503A products: pharmacy license, USP compliance documentation, COA, and prescription handling procedures. Always verify FDA registration status at fda.gov before ordering.
- Does ExaVeyra Sciences source from 503A or 503B facilities?
- ExaVeyra works only with a 503A pharmacy licensed by its state Board of Pharmacy, against a valid prescription for an individual patient. ExaVeyra does not work with a 503B outsourcing facility. All preparations come with full documentation including lot numbers, and a COA is available on request. Our founder, an M.Sc. organic chemist, reviews supplier documentation and manufacturing methodology before any product enters our catalog.
- Are exosomes regulated under 503A/503B?
- Exosomes occupy a complex regulatory space. MSC-derived exosomes are generally regulated as biological products under FDA oversight rather than as compounded drugs. The 503A/503B framework applies primarily to compounded drug products. Clinics should ensure exosome suppliers provide cGMP manufacturing documentation and COA regardless of the regulatory pathway.
- What is USP 797 and does it apply to my clinic?
- USP 797 is the United States Pharmacopeia standard for sterile compounding. It governs the preparation of sterile compounded medications including injectable formulations. If your clinic prepares or handles sterile compounded products, USP 797 compliance requirements apply. If you source pre-prepared sterile products from a 503B facility, the facility bears the USP 797 responsibility, not your clinic.
Related Resources
Exosome Sourcing Guide
How to evaluate exosome suppliers: analytical characterization and COA standards.
Read →Apply for Wholesale Access
Apply for NPI-verified wholesale access to our catalog.
Read →GLP-1 and Compounded Peptides in 2026
How shortage status, the 503A and 503B distinction and the 2026 peptide review decide what a pharmacy may compound.
Read →About Our Chemist Founder
Learn about the analytical chemistry background behind ExaVeyra's sourcing standards.
Read →Ready to Source Compliantly?
ExaVeyra Sciences supplies licensed clinics with peptides, biologics, and regenerative products, with compounded preparations prepared by a 503A pharmacy licensed by its state Board of Pharmacy, against a valid prescription for an individual patient. NPI-verified wholesale access, full COA documentation, and a chemist-reviewed supply chain.